Interventions for increasing immunosuppressant medication adherence showed no clear difference in taking adherence compared with standard care (low certainty).

1 finding from 1 review

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients 2022 · Cochrane Headline outcomes only
RR 1.09 [0.95, 1.27]
4 studies · 445 participants
Low

Interventions for increasing immunosuppressant medication adherence vs usual care

Dosing adherence · solid organ transplant recipients

Interventions for increasing immunosuppressant medication adherence may leads to higher dosing adherence compared with standard care (low certainty).

1 finding from 1 review

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients 2022 · Cochrane Headline outcomes only
RR 1.14 [1.03, 1.26]
8 studies · 713 participants
Low

Interventions for increasing immunosuppressant medication adherence vs usual care

Timing adherence · solid organ transplant recipients

Interventions for increasing immunosuppressant medication adherence showed no clear difference in timing adherence compared with standard care (low certainty).

1 finding from 1 review

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients 2022 · Cochrane Headline outcomes only
RR 1.1 [0.98, 1.23]
6 studies · 632 participants
Low

Interventions for increasing immunosuppressant medication adherence vs usual care

Drug holidays · solid organ transplant recipients

Interventions for increasing immunosuppressant medication adherence showed no clear difference in drug holidays compared with standard care (low certainty).

1 finding from 1 review

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients 2022 · Cochrane Headline outcomes only
RR 1.12 [0.77, 1.62]
4 studies · 445 participants
Low

Interventions for increasing immunosuppressant medication adherence vs usual care

Adherence · solid organ transplant recipients

It is very uncertain whether interventions for increasing immunosuppressant medication adherence changes self‐reported adherence (proportion) compared with standard care (very low certainty).

2 findings from 1 review

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients 2022 · Cochrane Headline outcomes only
RR 1.21 [0.99, 1.49]
9 studies · 755 participants
Very low
Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 471 participants
Very low

Interventions for increasing immunosuppressant medication adherence vs usual care

Proportion of immunosuppressant trough concentration levels at target · solid organ transplant recipients

It is very uncertain whether interventions for increasing immunosuppressant medication adherence changes proportion of immunosuppressant trough concentration levels at target compared with standard care (very low certainty).

1 finding from 1 review

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients 2022 · Cochrane Headline outcomes only
RR 0.98 [0.68, 1.4]
4 studies · 348 participants
Very low

Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment

All symptomatic CMV disease · solid organ transplant recipients with CMV viraemia

1 finding from 1 review

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 288 participants
Low

Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment

CMV organ involvement · solid organ transplant recipients with CMV viraemia

1 finding from 1 review

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 217 participants
Low

Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment

Acute rejection · solid organ transplant recipients with CMV viraemia

1 finding from 1 review

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 185 participants
Low

Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment

All‐cause mortality · solid organ transplant recipients with CMV viraemia

1 finding from 1 review

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 176 participants
Low

Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment

Graft loss · solid organ transplant recipients with CMV viraemia

1 finding from 1 review

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Very low

Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment

Leucopenia · solid organ transplant recipients with CMV viraemia

1 finding from 1 review

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 114 participants
Low

DPP‐4 inhibitors vs placebo

Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 51 participants
Very low